Ulcerative Colitis-Diagnostic and Therapeutic Algorithms

Dtsch Arztebl Int. 2020 Aug 17;117(33-34):564-574. doi: 10.3238/arztebl.2020.0564.

Abstract

Background: Ulcerative colitis is a chronic inflammatory bowel disease with an estimated 150 000 patients in Germany alone.

Methods: This review is based on publications about current diagnostic and therapeutic strategies for ulcerative colitis that were retrieved by a selective search in PubMed, and on current guidelines.

Results: The primary goal of treatment is endoscopically confirmed healing of the mucosa. Mesalamine, in various forms of administration, remains the standard treatment for uncomplicated ulcerative colitis. Its superiority over placebo has been confirmed in meta-analyses of randomized, controlled trials. Glucocorticoids are highly effective in the acute treatment of ulcerative colitis, but they should only be used over the short term, because of their marked side effects. Further drugs are available to treat patients with a more complicated disease course of ulcerative colitis, including azathioprine, biological agents, JAK inhibitors (among them TNF antibodies, biosimilars, ustekinumab, vedolizumab, and tofacitinib), and calcineurin inhibitors. Proctocolectomy should be considered in refractory cases, or in the presence of high-grade epithelial dysplasia. Ulcerative colitis beginning in childhood or adolescence is often characterized by rapid progression and frequent comorbidities that make its treatment a special challenge.

Conclusion: A wide variety of drugs are now available for the treatment of ulcerative colitis, enabling the individualized choice of the best treatment for each patient. Regular surveillance colonoscopies to rule out colon carcinoma should be scheduled at intervals that depend on risk stratification.

Publication types

  • Meta-Analysis
  • Review

MeSH terms

  • Adolescent
  • Algorithms
  • Biosimilar Pharmaceuticals*
  • Child
  • Colitis, Ulcerative* / diagnosis
  • Colitis, Ulcerative* / drug therapy
  • Germany
  • Humans
  • Mesalamine

Substances

  • Biosimilar Pharmaceuticals
  • Mesalamine